GLP-1 Market
LLY $1152.70 ▲ +0.0% NVO $43.24 ▲ +0.1% PFE $27.61 ▼ -0.1% VKTX $28.99 ▼ -1.3% KLRA $12.83 ▼ -0.7% GPCR $35.00 ▼ -0.3% RHHBY $54.04 ▼ -1.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ALN-APP

Company
Alnylam Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 19, 2026

Find a Clinical Trial Near Me

See recruiting studies for ALN-APP and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05231785

    A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

    Not yet reported Alnylam Pharmaceuticals 60 participants Est. completion 2029-04-20 8 sites Stand-alone
    Other conditions: Early-Onset Alzheimer Disease
    View official trial listing →
  • Recruiting NCT NCT07636811

    A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

    Not yet reported Alnylam Pharmaceuticals 58 participants Est. completion 2031-07-23 3 sites Stand-alone
    Other conditions: Down Syndrome-Associated Alzheimer's Disease (DS-AD)
    View official trial listing →
  • Active, not recruiting NCT NCT06393712

    A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

    Not yet reported Alnylam Pharmaceuticals 210 participants Est. completion 2029-12-14 57 sites Stand-alone
    Other conditions: Cerebral Amyloid Angiopathy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: ALN-APP, mivelsiran

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.